Nanocrine is pioneering a groundbreaking approach to understanding cellular communication at the molecular level. For the first time, Nanocrine’s technology enables direct observation of this live cell molecular communication by detecting, in real time, the messenger molecules released from live cells. This enables discovery of new molecular targets for therapeutic and diagnostic breakthroughs.

Nanocrine’s platform supports medical innovations in cancer metastasis, cellular senescence, immune system health, and neurodegenerative diseases. Nanocrine’s technology is already peer reviewed and proof-of-concept validated, with first sales anticipated in 2025.

Unique and groundbreaking intellectual property:

1. Exclusive license agreement with US Naval Research Lab

2. Large patent portfolio and significant trade secrets

3. US Army Research Laboratory partnership for manufacturing

Clear path to highly profitable business opportunity:

1. Recurring revenue with extremely high margin consumable products that employ existing lab equipment/microscopes

2. Does not require FDA regulatory clearance

3. Huge market with 455,000 research laboratories globally